FDA Moving Forward On Biosimilars: Setting User Fees


On May 10, 2011, the FDA published a Request for Comments on its proposal for setting user fees for 351(k) biosimilar applications: “Biologics Price Competition and Innovation Act of 2009; Options for a User Fee Program for Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 Through 2017; Request for Comments.”

Among the general principals stated for the proposal, the FDA expressed the desire to keep the 351(k) biosimilar user fees comparable to 351(a) user fees. See Kurt Karst’s 5/9/11 Post on the FDA Law Blog for a more detailed synopsis. Of course the industry is still eagerly awaiting the FDA’s guidance on establishing biosimilarity.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.